THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Users ask FDA panel for return of Tysabri

By Diedtra Henderson
Globe Staff / March 8, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

Dozens of multiple sclerosis patients told a Food and Drug Administration advisory panel yesterday that they should be allowed to take Tysabri, a promising treatment for MS pulled from the market last year after it was linked to a rare but deadly brain disease. (Full article: 776 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly